PT - JOURNAL ARTICLE AU - Platt, Daniel AU - Bose, Aritra AU - Levovitz, Chaya AU - Rhrissorrakrai, Kahn AU - Parida, Laxmi TI - Epidemiological topology data analysis links severe COVID-19 to RAAS and hyperlipidemia associated metabolic syndrome conditions AID - 10.1101/2022.03.31.22273239 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.31.22273239 4099 - http://medrxiv.org/content/early/2022/04/03/2022.03.31.22273239.short 4100 - http://medrxiv.org/content/early/2022/04/03/2022.03.31.22273239.full AB - The emergence of COVID19 created incredible worldwide challenges but offers unique opportunities to understand the physiology of its risk factors and their interactions with complex disease conditions, such as metabolic syndrome. Epidemiological analysis powered by topological data analysis (TDA) is a novel approach to uncover these clinically relevant interactions. Here TDA utilized Explorys data to discover associations among severe COVID19 and metabolic syndrome, and it explored the probative value of drug prescriptions to capture the involvement of RAAS and hypertension with COVID19 as well as modification of risk factor impact by hyperlipidemia on severe COVID19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by the Data Access and Control Board (IBM Watson Health) to further research into COVID-19 for the greater good. Patients in the US opt in by default and need to actively opt out. If they opt out, their data will not be part of the Explorys database used in this work. This database is fully de-identified and were accessed with protocols compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996 regulations; therefore, this study was exempted from Institutional Review Board approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.